ICT Gets Green Light to Build New Integrated Tissue Mill in North Wales, UK

According to Fastmarkets RISI, Italy’s Industrie Cartarie Tronchetti (ICT) has received the green light from local authorities to build a new 700,000 ft² integrated tissue production and conversion facility on the Northern Gateway site in Deeside, North Wales.

The Flintshire Council's planning committee gave its approval on March 30 after being recommended for approval by officers. ICT submitted proposals and a planning application for the Northern Gateway site in November last year. The new facility will deliver consumer tissue products marketed through retailer private labels and its own Foxy brand to the UK and Irish markets. The company added that the Welsh government has provided £5 million ($6.6million) to support the project.

According to ICT’s public consultation, the project will be carried out in three phases. “Phase one of the development will deliver a pulp warehouse, paper [machine], jumbo reel storage warehouse building, converting hall, dispatch area, workshop, staff social area, [an] automated 10-level finished product high bay warehouse, water treatment plant, mill station and two-story office building,” the consultation document said. Phase two will follow 12 months after the completion of phase one and will involve the start-up of tissue paper production. During this phase, an additional pulp warehouse, paper machine and jumbo reel storage warehouse will also be built next to the facilities completed during the first phase. Finally, phase three will consist of a third pulp warehouse, paper machine, boiler room, jumbo reel storage warehouse, converting hall and an extension to the proposed automated finished product high bay warehouse. This phase will only be launched if the facility needs to expand because of market demand for the finished product, ICT said.

The cost of the project, which will create some 400 jobs, was not disclosed. According to the local press, ICT said construction of the new facility would begin this year if the application was approved. The firm did not respond to request for comment.

Back to Tissue360 Newsletter